logo

Mersana Therapeutics, Inc. (MRSN)



Trade MRSN now with
  Date
  Headline
4/9/2021 8:13:29 AM Mersana Therapeutics Announces Initiation Of Patient Dosing In UPLIFT
3/11/2021 8:13:03 AM Mersana Therapeutics Appoints Allene Diaz To Board
9/17/2020 6:11:32 AM Mersana Therapeutics Reports Updated Interim Data From Ovarian Cancer Cohort Of XMT-1536 Phase 1 Expansion Study
8/31/2020 8:07:07 AM Mersana Therapeutics Appoints Chuck Miller As SVP Of Regulatory Affairs
6/23/2020 10:16:13 AM Stock Alert: Mersana At New High
5/29/2020 12:20:04 AM Mersana Therapeutics Prices Public Offering Of 8 Mln Shares At $19/Shr
4/15/2020 8:18:09 AM Mersana Therapeutics Names Martin Huber To Board
2/28/2020 6:11:11 AM Mersana Therapeutics Q4 Net Loss $16.2 Mln Or $0.34/Shr Vs Loss Of $22.4 Mln Or $0.97/Shr Last Year
1/7/2019 7:34:49 AM Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) FY19 Estimate To -2.79 From -2.48
1/7/2019 7:34:27 AM Wedbush Is Lowering Mersana Therapeutics, Inc. (MRSN) Q4 19 Estimate To -0.70 From -0.63